Bavarian Nordic A/S (BVNKF PINK) stock market data APIs
$35.9025
0(0%)
as of October 14, 2026
Try our APIs with
free plan!
Bavarian Nordic A/S Financial Data Overview
Price chart is built with
Anychart
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Prev. Close
35.9025
Open
35.9025
High
35.9025
Low
35.9025
52 wk Range
27.69-37.22
Market Cap
2 706 M
P/E Ratio
11.8618
Shares Outstanding
75 050 K
Revenue
6 338 M
EPS
1.4985
Beta
0.975
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bavarian Nordic A/S data using free add-ons & libraries
Get Bavarian Nordic A/S Fundamental Data
Bavarian Nordic A/S Fundamental data includes:
- Net Revenue: 6 338 M
- EBITDA: 1 782 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-21
- EPS/Forecast: 4.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bavarian Nordic A/S News
New
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S COPENHAGEN, Denmark, October 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Co...
Bavarian Nordic (CPSE:BAVA) Stock Could Be Undervalued Despite Its 64% Run
Bavarian Nordic has put in a strong three year share price run, while fresh optimism around its vaccines business has sharpened the focus on what the current valuation implies about the cash the compa...
Bavarian Nordic (CPSE:BAVA) Could Be 16% Below Fair Value As 2026 Guidance Rises
Bavarian Nordic (CPSE:BAVA) raised its full-year 2026 guidance following stronger Travel Health activity, with increased rabies vaccine demand in the US supporting both a higher revenue outlook and a ...
Bavarian Nordic rises after guidance upgrade on U.S. rabies vaccine demand
Investing.com -- Bavarian Nordic shares rose around 4% Thursday after the company raised its full-year 2026 guidance again, lifting its revenue and profitability outlook on stronger-than-expected sale...
Get Bavarian Nordic A/S fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.